The Molecular Cartography™ Company

We are bringing the latest advances in German precision engineering to the biotechnology field.

Together with our talented team of scientists and investors, we are poised to lead the next generation of single-cell analysis, which will enable scientists around the world the opportunity to apply the power of Molecular Cartography to their research, and gain new insights based on the highest-resolution view of single-cell spatial biology. Resolve Biosciences is privately held and headquartered in Monheim am Rhein, Germany.

01 — Investors


Investors

The $24 million Series A financing round was led by PS Capital Management and MasterMind Advisory Services and included participation from Alafi Capital, John Shoffner, and High Tech Gründerfonds.

The $71 million Series B financing was the latest round of funding led by Patient Square Capital and included participation from EDBI, PS Capital, Alafi Capital, and NRW.BANK, as well as other existing investors. The company has now raised more than $100 million.

 The Leadership Team 

02 — The Leadership Team


The Leadership Team

  • "I always wanted to work for a company where high end technology that serves a compelling purpose is developed, and cross functional teamwork with a focus on science is the rule and not the exception." Oliver Dick Chief Operating Officer
  • "Our Molecular Cartography platform provides exquisite spatial context so scientists can focus on what matters. Through this powerful technology, researchers can uncover cellular and functional insights with a resolution previously unseen." Joanne Dimitrakopoulos Global Commercial Marketing Leader
  • "It's essential for me to have a purposeful life, to create a compelling future for the next generation. The science we are driving at Resolve is impactful, providing researchers novel insights into the most daunting challenges of elucidating disease and developing cures." Jason T. Gammack Chief Executive Officer
  • "I’m excited about the opportunity to shape a talented, hardworking team that brings the power of our Molecular CartographyTM technology to our customers." Peter Grünefeld Head of Operation
  • "I am convinced that our Molecular CartographyTM technology will have a strong impact in resolving new findings in the spatio-temporal function of organs and organisms." Christian Korfhage Head of Applications
  • "I have been asked many times what questions researchers will be able to answer using Resolve's Molecular CartographyTM. My honest answer has always been: I do not know. If I knew, our technology would be far less exciting than it actually is!" Frank Reinecke Head of Bioinformatics
  • "I want to build a powerful team where people can bring in their skills and knowledge while creating a culture of respect, trust and appreciation. This unique opportunity in making a difference through people is why I put all my energy and passion into my work at Resolve." Bettina Stolz Chief of Staff
  • "Resolve offers the opportunity to build a global business working with exceptional people on an exciting technology. Our next-generation molecular analysis technology is enabling scientists to find answers to the most complex challenges in biology." Erik Wiberg Chief Financial Officer
  • "My mission is to stay at the frontier to advance omics tools. I truly believe in the scientific foundation of Resolve's technology and am excited about the unlimited potential of the Molecular Cartography platform we are developing. Frank Zhong Chief Technology Officer
  • "My mission is to stay at the frontier to advance omics tools. I truly believe in the scientific foundation of Resolve's technology and am excited about the unlimited potential of the Molecular Cartography platform we are developing." Frank Zhong Chief Technology Officer

 The Offices 

04 — Do you want to join us?


Do you want to join us?

This is the perfect opportunity for a successful candidate to become a part of a highly motivated, agile, and international team in an attractive work environment with excellent career opportunities and flat hierarchies.

You will contribute to develop our cutting-edge technology with the clear goal to offer products worldwide, and you will influence both our products and clients. We provide space for creativity and flexible working hours and look forward for new members to join us on an exciting journey into a new field of biotechnology. Still in the start-up phase, we wish to collaborate and grow together with forward-minded people.

Join us

Image of

Close

Laura Furmanski

Laura is a Partner at Patient Square Capital and Head of Patient Square Insights. Laura has 20 years of health care experience across consulting and operating roles, most recently as Managing Director & Partner at Boston Consulting Group. While at BCG, Laura worked with biopharma and medical device companies on a range of R&D, market access, and broader strategy topics, and she played a lead role in creating BCG’s data and analytics offerings for the health care sector.

Prior to BCG, Laura created and was SVP and Head of the Bioinformatics Business Area for QIAGEN, a life science company. In that capacity, her team built and launched the company’s genomic clinical decision support platform for oncology and rare diseases. She managed the engineering and commercial teams that delivered a portfolio of innovative informatics products to biopharmaceutical companies, academic research institutions, and clinical labs. Laura was also a Partner at McKinsey & Co, where she worked across the entire health care value chain.

Laura holds a Ph.D. in Cognitive Neuroscience from UCLA and a B.A. from Stanford University.

Aristotelis Nastos

Aristotelis Nastos is a German and Greek citizen living in London (UK). He is a scientist by training with a PhD in Molecular and Cell Biology. After several years of research experience in academia as a Post Doc at the King’s College London, an International Research Fellow of the Welcome Trust (UK) and a Research Group Leader of the German Diabetes Research Foundation in Düsseldorf he now works in the European Venture Capital Industry. In this role he has actively participated in numerous financing and M&A transactions. Telis leads the life science investment activities of NRW.BANK, is responsible for more than 30 portfolio companies and projects and has accompanied several successful exits such as Rigontec, Cevec, Direvo, Scienion. Due to his longstanding activities he has acquired a deep insight and a broad network in the global Life Science and financing industry. He also serves as a member of the Board in a variety of international Life Science companies.

Christopher Alafi

Christopher has been a General Partner of Alafi Capital Company, LLC, a venture capital firm since 1995. He was previously a Physiology and Anatomy teacher at Santa Monica College, a visiting scholar in the Department of Chemistry at Stanford University and a researcher at DNAX. Christopher previously served as a director of Intra-Cellular Therapies Inc., ISTO Technologies, Coley Pharmaceutical Group, Inc., CyberGold, Inc. and Stereotaxis, Inc.

Christopher received a B.A. in Biology from Pomona College and a D.Phil. in Biochemistry from the University of Oxford.

Peer M. Schatz

Peer is co-founder of Resolve Biosciences and Chairman of the Board. He is the Managing Director of PS Capital Management GmbH, which provides capital and support to emerging companies, primarily in the Life Sciences industry. Prior to cofounding Resolve Biosciences he was long-time Chief Executive Officer of QIAGEN N.V. (Nasdaq: QGEN; Frankfurt: QIA), a leading provider of molecular sample and assay technologies. From 1993 to 2019, he led QIAGEN's rapid expansion from a start-up company with $2 million in sales into a global leader in molecular testing with over $1.6 billion in revenues. Peer currently serves on the Supervisory Boards of Siemens Healthineers AG and Centogene NV. He served as a founding member of the German Corporate Governance Commission, as a Vice Chairman of the Supervisory Board of Evotec AG, as Vice Chairman of AdvaMedDx (an in-vitro diagnostics industry organization in the United States) and as Director of the U.S. Analytical & Life Science and Diagnostic Association (ALDA). He graduated from the University of St. Gallen, Switzerland, with a master’s degree in Finance and from the University of Chicago Graduate School of Business with an MBA.